New and Old Key Players in Liver Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242417152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ángel M Cuesta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 282 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Spanish Ministry of Economy and Competitiveness, Spanish Ministry of Education.
Abstract (Originalsprache)
Liver cancer represents a major health problem worldwide with growing incidence and high mortality, hepatocellular carcinoma (HCC) being the most frequent. Hepatocytes are likely the cellular origin of most HCCs through the accumulation of genetic alterations, although hepatic progenitor cells (HPCs) might also be candidates in specific cases, as discussed here. HCC usually develops in a context of chronic inflammation, fibrosis, and cirrhosis, although the role of fibrosis is controversial. The interplay between hepatocytes, immune cells and hepatic stellate cells is a key issue. This review summarizes critical aspects of the liver tumor microenvironment paying special attention to platelets as new key players, which exert both pro- and anti-tumor effects, determined by specific contexts and a tight regulation of platelet signaling. Additionally, the relevance of specific signaling pathways, mainly HGF/MET, EGFR and TGF-β is discussed. HGF and TGF-β are produced by different liver cells and platelets and regulate not only tumor cell fate but also HPCs, inflammation and fibrosis, these being key players in these processes. The role of C3G/RAPGEF1, required for the proper function of HGF/MET signaling in HCC and HPCs, is highlighted, due to its ability to promote HCC growth and, regulate HPC fate and platelet-mediated actions on liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain.
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD-ISCIII), 28040 Madrid, Spain.
ORCID-Profile: Ángel M Cuesta, Alvaro Gutierrez-Uzquiza, Blanca Herrera, Aránzazu Sánchez, Almudena Porras
Förderung
- Agencia Estatal de Investigación
- Spanish Ministry of Economy and Competitiveness
- Spanish Ministry of Education
Zitieren
APA
Cuesta, Á. M., Palao, N., Bragado, P., Gutierrez-Uzquiza, A., Herrera, B., Sánchez, A., & Porras, A. (2023). New and Old Key Players in Liver Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417152
Vancouver
Cuesta ÁM, Palao N, Bragado P, Gutierrez-Uzquiza A, Herrera B, Sánchez A, et al. New and Old Key Players in Liver Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417152
BibTeX
@article{Cuesta2023,
author = {Cuesta, Ángel M and Palao, Nerea and Bragado, Paloma and Gutierrez-Uzquiza, Alvaro and Herrera, Blanca and Sánchez, Aránzazu and Porras, Almudena},
title = {New and Old Key Players in Liver Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242417152}
}
EUVIMED